Investor Relations



Bio-Techne to host a conference call on
Tuesday morning, May 2, 2017, at 8:00 a.m. CDT
to review third quarter fiscal 2017 financial results.

A replay of the call is available: Launch Rebroadcast



Register to receive Bio-Techne Investor Relations Email Alerts Sign Up

TECH vs SPX 500 IndexSales by Geographic RegionBio-Techne Product Life Cycle
Fast Facts
  • $499 million in net sales
    (July 2015 to June 2016)
  • ~ 1,650 employees worldwide
  • ~ 275,000 products
  • ~ 330,000 journal citations
  • Incorporated in Minneapolis, Minnesota, in 1981

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota. The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Clinical Controls Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,650 employees worldwide. For more information on
Bio-Techne and its brands, please visit our brands.

2016 Annual Report
Press Contact Info

David Clair
TEL 646-277-1266